Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

Hi, everyone, and welcome. I'm Najat Khan, Recursion's Chief R&D and Chief Commercial Officer and incoming CEO and President. Let's jump right in. Today is an important moment for Recursion, for our ...

This course is available on the MSc in Applicable Mathematics, MSc in Data Science, MSc in Operations Research & Analytics, MSc in Statistics, MSc in Statistics (Financial Statistics), MSc in ...

Fundamental concepts of computers, computation and programming; history and principles of computing; problem solving; input, output; data representation, storage, and file organization; computer ...

Accurate classification of wetland vegetation is essential for biodiversity conservation and carbon cycle monitoring. This study developed an adaptive ...

TL;DR: The Great Flood starts as a familiar Korean disaster film before mutating into an unsettling sci-fi meditation on emotional optimization and algorithmic storytelling. It’s messy, ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion describes itself as a clinical stage TechBio company that uses its proprietary Recursion OS platform to analyze biological and chemical datasets. The company operates laboratories capable of ...

Additionally, Recursion shared promising results from its ongoing Phase 1b/2 TUPELO trial for the drug REC-4881, showing significant polyp reduction in patients with familial adenomatous polyposis.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...